Story perspectives

FTC Exposes PBMs Inflating Generic Drug Prices 1,000%

2/4/2025

42 10

Summary

Story summary

The FTC reveals that Pharmacy Benefit Managers (PBMs) inflate generic drug prices by over 1,000%, affecting 80% of U.S. prescriptions.
Major PBMs like Express Scripts, CVS Caremark, and Optum RX profit significantly from these price markups.
Consumers experience stark price differences; a $10 drug can be billed at $1,000 through insurance.
Local pharmacists urge reforms for transparency to protect independent pharmacies from PBM practices.
Rising drug costs stem from PBM lobbying and limited competition, leading to demands for legislative change.

History

Historical Context

The FTC's findings on Pharmacy Benefit Managers (PBMs) echo past healthcare reforms. In the late 1990s, rising drug costs prompted scrutiny of pharmaceutical pricing and insurance practices. Historical lobbying by PBMs parallels today's calls for transparency, reflecting ongoing struggles against inflated drug prices and the need for reform in U.S. healthcare.

1 of 2

Story summary

The FTC reveals that Pharmacy Benefit Managers (PBMs) inflate generic drug prices by over 1,000%, affecting 80% of U.S. prescriptions.
Major PBMs like Express Scripts, CVS Caremark, and Optum RX profit significantly from these price markups.
Consumers experience stark price differences; a $10 drug can be billed at $1,000 through insurance.
Local pharmacists urge reforms for transparency to protect independent pharmacies from PBM practices.
Rising drug costs stem from PBM lobbying and limited competition, leading to demands for legislative change.

1 / 2